entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 18:15:40 - browse：1

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Can food be medicine? And other questions about a new push

hotspot

WSS

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Make 'food is medicine' a key part of White House nutrition meeting

Inside the fall of star MIT scientist David Sabatini

Doctor appointment wait times are getting worse

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Arc Institute generative AI designs new CRISPR systems

explore

entertainment

entertainment

Psychedelics group wrestles with new pharma identity

Helping hospitals and community health centers plan for resilience

Medical records are filled with copy

Australia's humpback populations rebound raising hopes of marine scientists

Sports medicine is finally prioritizing gender equality

Option Care buys Amedisys in $3.6 billion home care deal

Medical leaders decry Supreme Court decision on affirmative action

Second House panel advances two

Duchenne breakthrough therapy leaves behind pioneering families

Anxious about a speech? A startup wants you to pop a minty cardiac drug

leisure time

Readers respond to H5N1 and livestock movements, and more

Grail is spending more than ever lobbying Congress

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Grail is spending more than ever lobbying Congress

Helping hospitals and community health centers plan for resilience

Military medical care influenced by rank and race, new study finds

hotspot

hotspot

focus

Wikipedia